Abstract
Aim. To investigate the effect of daikenchuto (TJ-100; DKT) for ulcerative colitis (UC) model mouse and assess its anti-inflammatory mechanisms. Methods. We evaluated the effects of DKT on dextran sulfate sodium- (DSS-) induced experimental colitis. First, we assessed the short-term effects of DKT using two groups: 5% DSS group and 5% DSS with DKT group. Colon length; histological scores; and interleukin- (IL-) 10, IL-1β, and tumor necrosis factor-α mRNA expression profiles were analyzed using real-time PCR. Second, we assessed the long-term effects of DKT, by comparing survival time between 2% DSS and 2% DSS with DKT groups. Results. After 7 days, the colon lengths of DSS + DKT group were longer than those of the DSS group (mean values: 6.11 versus 5.69 cm, p < 0.05). Furthermore, compared to DSS group, the DSS + DKT group maintained significantly higher levels of serum hemoglobin (13.1 versus 10.7 g/dL, p < 0.05) and exhibited significantly higher expression levels of IL-10 (p < 0.05). The 2% DSS + DKT group exhibited significantly longer survival time than the 2% DSS group (70 versus 44 days, p < 0.01). Conclusion. Our results indicate that DKT prevented inflammation in the colon, indicating its potential as a new therapeutic agent for UC.
Highlights
Ulcerative colitis (UC) is a chronic, recurrent inflammatory disease of the colon and rectum, characterized by bloody diarrhea, intestinal mucosal ulceration, and infiltration of neutrophils and lymphocytes into the mucous membrane [1]
We evaluated the effects of DKT on the development of dextran sulfate sodium- (DSS-)induced experimental colitis in mice
The purpose of this study was to elucidate the effects of DKT on Dextran sulfate sodium (DSS)-induced colitis, and our results showed that DKT attenuated DSS-induced colitis in mice and prolonged the survival of DSS-treated mice
Summary
Ulcerative colitis (UC) is a chronic, recurrent inflammatory disease of the colon and rectum, characterized by bloody diarrhea, intestinal mucosal ulceration, and infiltration of neutrophils and lymphocytes into the mucous membrane [1] Multiple factors such as environmental changes, gene variations, and gut microbiota were thought to be associated with UC, its pathogenesis has not been fully elucidated [2]. Novel therapeutic agents to treat UC, such as tacrolimus, infliximab, and adalimumab, have become available in Japan, and these new drugs have enabled many patients to avoid surgery [3,4,5]. Many of the therapeutic agents used to treat UC are immunosuppressants, and because UC commonly develops in elderly patients, there is a real risk of complications due to infection [6]. Some studies have reported the clinical efficacy of DKT in treating postoperative paralytic ileus, and recent research has shown that DKT has an inhibitory effect on inflammation in Crohn’s
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
